Climb Bio Inc Sustainability Reports
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for patients living with immune-mediated diseases. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00ZNKL0L5
1 reports from 2024 to 2024
Company Profile
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for patients living with immune-mediated diseases. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
